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Background: It has been shown in many solid tumors that the overexpression of the pro-survival Bcl-2 family
members Bcl-xL and Mcl-1 confers resistance to a variety of chemotherapeutic agents. Mcl-1 is a critical survival
protein in a variety of cell lineages and is critically regulated via ubiquitination.
Methods: The Mcl-1, Bcl-xL and USP9X expression patterns in human lung and colon adenocarcinomas were
evaluated via immunohistochemistry. Interaction between USP9X and Mcl-1 was demonstrated by
immunoprecipitation-western blotting. The protein expression profiles of Mcl-1, Bcl-xL and USP9X in multiple cancer
cell lines were determined by western blotting. Annexin-V staining and cleaved PARP western blotting were used
to assay for apoptosis. The cellular toxicities after various treatments were measured via the XTT assay.
Results: In our current analysis of colon and lung cancer samples, we demonstrate that Mcl-1 and Bcl-xL are
overexpressed and also co-exist in many tumors and that the expression levels of both genes correlate with the
clinical staging. The downregulation of Mcl-1 or Bcl-xL via RNAi was found to increase the sensitivity of the tumor
cells to chemotherapy. Furthermore, our analyses revealed that USP9X expression correlates with that of Mcl-1 in
human cancer tissue samples. We additionally found that the USP9X inhibitor WP1130 promotes Mcl-1 degradation
and increases tumor cell sensitivity to chemotherapies. Moreover, the combination of WP1130 and ABT-737, a
well-documented Bcl-xL inhibitor, demonstrated a chemotherapeutic synergy and promoted apoptosis in different
tumor cells.
Conclusion: Mcl-1, Bcl-xL and USP9X overexpression are tumor survival mechanisms protective against
chemotherapy. USP9X inhibition increases tumor cell sensitivity to various chemotherapeutic agents including Bcl-
2/Bcl-xL inhibitors.
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Despite improvements in the accuracy of clinical staging
for solid cancers, the survival rates for patients affected
with these tumor types have improved only modestly
over the last few decades. Many solid tumors are unre-
sponsive to conventional therapy due to the resistance of
the tumor cells to programmed cell death. The downre-
gulation of Bcl-xL has been shown to induce apoptosis
and increase chemosensitivity [1,2] but resistance to
chemotherapy is still observed in some cancer cells even* Correspondence: xcao@swmail.sw.org
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distribution, and reproduction in any mediumafter Bcl-2/Bcl-xL inhibition [3,4]. Recent reports have
revealed that the overexpression of Mcl-1 compensates
for the loss of the anti-apoptotic function of Bcl-2/xL
[5,6]. A reduction in Mcl-1 significantly enhances the
sensitivity of cancer cells to ABT-737 and other che-
motherapeutics [7-9]. In addition, the forced overexpres-
sion of Mcl-1 in transgenic mice leads to a significantly
increased incidence of B-cell lymphoma [10]. Hence, the
cumulative evidence to date suggests that Mcl-1 overex-
pression may function as an additional survival mechan-
ism that protects cancer cells against conventional
therapies.
Mcl-1 expression, just like Bcl-xL expression, is highly
induced under conditions that are conducive to survivalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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factors [11,12]. Mitogen-activated protein kinase (MAPK)-
phosphatidylinositol-3 (PI3K)- and Janus kinase (JAK)/sig-
nal transducer and activator of transcription (STAT)-
dependent pathways have all been implicated in the
stimulation of Mcl-1 transcription, acting via specific
transcription factor response elements in the Mcl-1 gene
promoter [13-15]. However, the direct phosphorylation
of Mcl-1 also plays an important role in controlling
its expression and function. Mcl-1 can be phosphoryl-
ated in its PEST region, and thus stabilized, upon ERK
activation [16].
Additionally, Mcl-1 is regulated by a subtle balance be-
tween ubiquitination and deubiquitination. Two E3
ligases have been implicated in Mcl-1 turnover. The first
of these is Mcl-1-ubiquitinating ligase E3 (MULE) which
possesses a BH3 domain similar to that of proapoptotic
BAK that allows it to target Mcl-1 [17]. Interestingly, al-
though the RNAi-mediated silencing of MULE slows the
Mcl-1 turnover rate, degradation of this protein never-
theless still occurs, suggesting that additional pathways
can promote Mcl-1 elimination [18]. The second E3 lig-
ase, SCFβ-TrCP, was discovered to only recognize Mcl-1
that has been phosphorylated by GSK3 at Ser159 [19].
This interaction between SCFβ-TrCP and Mcl-1 is facili-
tated by phosphorylation of the same serine and threo-
nine residues that have been identified previously as
potential sites of recognition by the X-linked ubiquitin
specific peptidase 9 (USP9X), a deubiquitinase (DUB)
[20]. Hence, it is possible that SCFβ-TrCP and USP9X
compete for Mcl-1 binding. USP9X binds Mcl-1 protein
and removes the Lys 48-linked polyubiquitin chains that
normally mark it for proteasomal degradation. Mcl-1
ubiquitination is thus offset by the activities of USP9X
and it has been reported that increased USP9X expres-
sion correlates with increased Mcl-1 protein levels and a
poor prognosis in lymphoma patients [20]. The silencing
of USP9X using siRNAs increases the sensitivity of CML
cells, to imatinib and other apoptotic stimuli [21]. The
deubiquitination activities of USP9X can be inhibited by
WP1130, a partially selective DUB inhibitor [22]. It has
been demonstrated in this regard that a reduction in the
Mcl-1 levels in WP1130-treated cancer cells parallels the
inhibition of USP9X activity.
In our current study, we further tested the hypothesis
that Mcl-1 and Bcl-xL are both overexpressed in colon
and lung cancers. Our analysis reveals that the overex-
pression of both of these anti-apoptotic proteins causes
resistance to chemotherapeutic agents. In addition, the
blocking of USP9X activities using a small-molecule in-
hibitor decreases Mcl-1 expression by promoting its
degradation and thus sensitizes tumor cells to che-
motherapeutic agents.Methods
Cell culture
I45, REN (human mesothelioma cell lines), A549, H1299
and H23 (lung cancer cell lines) as well as DLD-1 and
HCT116 (colon cancer cell lines) were purchased from
the American Type Culture Collection (Manassas, VA).
DLD-1, H1299, H23, I45 and REN were cultured in 10%
fetal bovine serum (FBS)-supplemented RPMI 1640
medium. A549 cells were cultured in 10% FBS-
supplemented F12 medium. HCT-116 cells were cul-
tured in McCoy’s 5A medium containing 10% fetal
bovine serum. Authentication of these cell lines was per-
formed by the ATCC.
Reagents
Cycloheximide, 5-FU, Taxol, PS341, WP1130 and ABT-
737 were obtained from Selleck Chemicals (Houston,
TX). The HDAC inhibitor SAHA (suberoylanilide
hydroxamic acid) was purchased from Biovision (Moun-
tain View, CA). The rabbit anti-human USP9X poly-
clonal antibody used was obtained from Bethyl
Laboratories (Montgomery, TX). Rabbit antibodies
against Bcl-xL and Mcl-1 were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA). Mouse
monoclonal anti β-actin was obtained from Sigma (Saint
Louis, MO). The siRNA transfection reagents, and siR-
NAs targeting Bcl-xL, Mcl-1 and a control scrambled
siRNA, were obtained from Ambion Biotechnology, Inc.
(Austin, TX).
Apoptosis assay
After various treatments, cancer cells were stained for
Annexin-V using a FITC–Annexin-V staining kit (Invi-
trogen, Carlsbad, CA) and then measured with BD
FACSCanto II Flow cytometry. Flow cytometry data
were analyzed using FlowJo software (Tree Star Corp,
Ashland, OR).
Cell proliferation assays
The effects of various inhibitors on cell viability
were assessed in quadruplicate samples using the 2,3-bis
(2-methoxy-4-nitro-5-sulfophenly)-5-[(phenylamino) car-
bonyl]-2H-tetrazolium hydroxide (XTT) assay (Trevigen,
Inc. Gaithersburg, MD). Cancer cells were seeded and
incubated in 96-well, flat-bottomed plates in 10% FBS-
supplemented culture medium 24 hours before drug treat-
ment. The cells were then exposed to various inhibitors at
the indicated concentrations at 37°C in 5% CO2 for 72
hours. The medium was removed and replaced with 150
μl fresh medium containing XTT, and the cells were fur-
ther cultured in the CO2 incubator at 37°C for 5 hours.
Absorbance was determined on a plate reader at 492 nm.
Figure 1 (See legend on next page.)
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Figure 1 Mcl-1 and Bcl-xL are co-overexpressed in multiple solid tumor types. (a) Mcl-1 and Bcl-xL expression patterns in lung and colon
adenocarcinomas. The co-existence of Mcl-1 and Bcl-xL expression in tumor cells on the tissue slides was assessed using the Fisher exact and
Chi-square tests. (b) The association between Bcl-xL or Mcl-1 expression and clinical staging in colon cancer samples was measured using linear
regression. Protein expression levels between stages were compared using pre-planned contrasts. The mean levels within each stage, plus or
minus one standard error, are plotted.
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Cancer cells were lysed using urea containing lysis buffer
and equal amounts of total proteins were resolved on
4–20% Tris-glycine gels and transferred onto a nitrocel-
lulose membrane. The membranes were then co-
incubated with a rabbit anti-human Bcl-xL polyclonal
antibody, a rabbit anti-human Mcl-1 monoclonal anti-
body, rabbit anti-human USP9X polyclonal antibody and
a mouse anti-human β-actin antibody overnight. Anti-
body binding was then detected using chemilumines-
cence (Cell Signaling Technology, Danvers, MA) and
signals were visualized by autoradiography.
Clinical tumor specimens and immunohistochemistry
Formalin-fixed, paraffin-embedded tissue from colon
adenocarcinoma and lung adenocarcinoma were exam-
ined for expression levels of Mcl-1, Bcl-xL and USP9X
protein. All samples were histologically confirmed and
patient identities were removed. These tumor tissue
slides were deparaffinized in xylene, subjected to antigen
retrieval, and following endogenous peroxidase quench-
ing were blocked in horse serum and incubated over-
night with a rabbit anti-human Bcl-xL polyclonal
antibody, rabbit anti-human Mcl-1 monoclonal anti-
body, or rabbit anti-human USP9X polyclonal antibody.
The slides were then incubated with a biotinylated goat
secondary anti-rabbit antibody (Vector Laboratories,
Burlingame, CA) for 30 minutes and the resulting sig-
nals were detected using streptavidin-biotin-peroxidase
complex (Vector Laboratories) and diaminobenzidine
(DAB) (Vector Laboratories). The slides were counter-
stained with hematoxylin (Sigma-Aldrich, St. Louis,
MO) and the images were captured with a digital cam-
era. The signals were then measured using ImageScope
Software (Aperio Technologies Vista, CA). Positivity was
quantified by specifying a hue value of 0.1 and hue width
of 0.33 for a standardized area of the tumor tissue.
Approval for this study was obtained from the Institu-
tional Ethics Review Board at the Scott & White Me-
morial Hospital and Texas A &M Health Science
Center. The study was conducted in compliance with
the Helsinki Declaration.
Statistics
The co-existence of Mcl-1 and either Bcl-xL or USP9X
expression in tumor cells were assessed using the Chi-square and Fisher exact tests. A Pearson correlation be-
tween the Bcl-xL, USP9X and Mcl-1 expression profiles
was calculated using R statistical software (http://www.r-
project.org). The association of protein expression and
clinical staging of the tumor samples was determined
using linear regression.Results
Mcl-1 and Bcl-xL are co-overexpressed in multiple solid
tumor types
To evaluate the correlation between Bcl-xL and Mcl-1
expression in lung and colon cancer, we analyzed human
non-small cell lung adenocarcinoma and colon adeno-
carcinoma samples by immunohistochemistry using
antibodies against these two proteins. As shown in
Figure 1a, there were strong associations observed be-
tween the expression of Mcl-1 and that of Bcl-xL in both
the lung and colon cancer samples. In the 117 human
colon cancer samples we analyzed, 47 specimens stained
positively for both proteins and a further 29 samples
showed weak co-staining for both factors (Chi-squared
test, P=0.0028; Fisher test, P=0.0021). In the 81 lung
cancer samples tested in this analysis, 51 samples
showed strong positive staining for both proteins and
five samples showed co-staining at low levels (Fisher
exact test, P=0.045; Chi-square value of 4.612,
P=0.0319). There were further relationships observed be-
tween Mcl-1 and Bcl-xL protein expression and tumor
staging in colon cancer samples (Figure 1b). Mcl-1 ex-
pression was found to increase with the staging grade
(P=0.0042), (P=0.0036 from I to II; P=0.016 from I to III;
and P=0.090 from I to IV). Bcl-xL expression was also
found to be significantly associated with staging
(P=0.0054), with stage I lesions showing significantly dif-
ferent levels of this protein compared with stage III
(P=0.033) and stage IV (P = 0.004) tumors. Tumor sta-
ging data were not available for the lung cancer samples.Tumor cells expressing high levels of Mcl-1 and Bcl-xL
protein exhibit chemoresistance
To test the hypothesis that high Mcl-1 and Bcl-xL
expression contributes to drug resistance, including re-
sistance to Bcl-xL inhibitors, the baseline protein expres-
sions of Bcl-xL and Mcl-1 in multiple cell lines were
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demonstrated the concurrent expression of both Mcl-1
and Bcl-xL in most cell lines, corroborating the immu-
nostaining results in both lung and colon tumor tissues
shown in Figure 1. To evaluate the role of Mcl-1 and
Bcl-xL in tumor cell survival, knockdowns of each factor
alone and in combination were performed with smallFigure 2 (See legend on next page.)interfering RNAs (siRNAs) in A549, REN and H1299
cell lines that overexpress both Mcl-1 and Bcl-xL pro-
teins. Unilateral Mcl-1 reduction caused cell death at
10%, 45% and 50% levels in A549, REN and H1299 cells,
respectively, whilst a Bcl-xL knockdown alone caused
50%, 37% and 40% rates of cell death in these cells. How-
ever, the co-inhibition of both proteins by RNAi resulted
(See figure on previous page.)
Figure 2 Tumor cells expressing high levels of Mcl-1 and Bcl-xL protein exhibit chemoresistance. (a) Basal expression of Mcl-1 and Bcl-xL
in various lung, colon and mesothelioma cancer cell lines determined by western blot analysis. (b) Mcl-1 and Bcl-xL contribute to cancer cell
survival. A549, REN and H1299 cells were transfected with control siRNA, Mcl-1 siRNA, Bcl-xL siRNA, or a combination of both, via electroporation
using Nucleofector II from Lonza (Switzerland). The cells were then seeded in 96 well plates, and cultured for 72 h. An XTT assay was performed
following the manufacturer’s protocol to evaluate cell viability. Western blotting was used to measure the Bcl-xL and Mcl-1 protein levels after
specific siRNA transfection. (c) To determine the chemo-response of DLD-1, H23, H1299, and A549 cells to SAHA and ABT-737, the cells were
plated at a density of 5000 per well and treated with different concentrations of these chemotherapeutic agents over a 72 h incubation. An XTT
assay was then performed in quadruplicate for each treatment condition and the experiments were repeated three times. (d) Mcl-1 was knocked
down by siRNA in A549, REN and H1299 cells which were plated in a 96 well format. A control siRNA experiment was included. The cells were
then treated with DMSO (control) or ABT-737 (IC30 doses) for 72 h, followed by an XTT assay for cell viability. The results were averaged from
quadruplicate analyses for each treatment condition and the experiments were repeated three times.
Peddaboina et al. BMC Cancer 2012, 12:541 Page 6 of 12
http://www.biomedcentral.com/1471-2407/12/541in low cell survival with an almost 80-90% drop in viabil-
ity (Figure 2b). Bcl-xl and Mcl-1 reductions via siRNAs
were demonstrated using western blotting (Figure 2b).
To examine whether Mcl-1 contributes to Bcl-xL in-
hibitor resistance, we next evaluated the viability of vari-
ous cell lines with different Bcl-xL and Mcl-1 expression
profiles in the presence of ABT-737 (Figure 2c). The
colon adenocarcinoma cell line DLD-1, which expresses
relatively lower Mcl-1 levels, but high Bcl-xL expression,
was found to be sensitive to Bcl-xL inhibition via ABT-
737. A549 and H1299 cells, which express relatively high
levels of Bcl-xL and Mcl-1, and H23 cells, which shows
strong Mcl-1 expression and low Bcl-xL expression, all
demonstrated resistance to ABT-737. Similar levels of
resistance to SAHA, a histone deacetylase inhibitor, were
only observed in those cell lines with both Bcl-xL and
Mcl-1 overexpressions. To further assess the role of
Mcl-1 in the resistance to Bcl-xL inhibition, A549,
H1299 and REN cells were transfected with control siR-
NAs or Mcl-1 siRNAs and then exposed to ABT-737 at
their calculated IC30 doses (10, 12 and 20 μM, respect-
ively). After Mcl-1 reduction and ABT-737 treatment,
survival fractions of A549, H1299, and REN cells were
decreased to 10%, 5% and 19% respectively, while in
control siRNA transfected and ABT-737 treated cells
showed 70%-75% viabilities (Figure 2d). This data indi-
cate that reduced Mcl-1 expression enhances the
sensitization of cells to Bcl-xl inhibition.
Mcl-1 and USP9X are both overexpressed in colon and
lung cancers
USP9X was recently identified as an Mcl-1 deubiquiti-
nase [20]. To further elucidate the relationship between
USP9X and Mcl-1 in clinical samples, the protein ex-
pression levels of these factors were evaluated in a panel
of 94 human non-small cell lung adenocarcinoma speci-
mens by immunohistochemistry (Figure 3a). The results
demonstrated a strong correlation between USP9X and
Mcl-1 expression levels (r=0.745, P<0.001; Figure 3c).
We performed the same analyses in a series of 79 colon
tumor samples (Figure 3b) and observed a moderatecorrelation between the expression of USP9X and Mcl-1
(r=0.345, P<0.001; Figure 3d). In terms of a linear model
for the expression of USP9X in colon carcinoma, this
was found to be significant (P=0.00083). In terms of
tumor staging, we found that stages I-II (P=0.00043),
I-III (P<0.001) and I-IV (P=0.0011) were significantly dif-
ferent. In each case the higher stage showed higher ex-
pression values. The difference between stages II and III
(P=0.032) was also found to be significant, with stage III
tissues showing higher expression of USP9X (Figure 3e).
USP9X activity regulates Mcl-1 expression
To explore the role of USP9X inhibition in Mcl-1 ex-
pression regulation, H1299 cells were exposed to the
USP9X inhibitor WP1130 [23] for six hours and Mcl-1
expression was subsequently examined via western blot-
ting. As shown in Figure 4a, exposure to WP1130 led to
a 50% reduction of Mcl-1 expression in these cells,
whereas the Bcl-xL expression levels remained un-
changed. To obtain additional evidence that USP9X pro-
tects Mcl-1 from degradation, A549 cells were exposed
to the protein synthesis inhibitor cycloheximide (CHX)
alone or in combination with WP1130. The CHX and
WP1130 combination at six hours caused a significantly
higher reduction of Mcl-1 than CHX alone. This result
indicates that the inhibition of USP9X accelerates Mcl-1
degradation (Figure 4b) and hence that USP9X activities
are critical for Mcl-1 stability. Immunoprecipitation (IP)
western blotting was employed to further explore the
physical interaction between USP9X and Mcl-1 in can-
cer cells and a strong direct association was observed
(Figure 4c). To further probe the role of USP9X in pre-
venting Mcl-1 degradation, A549 lung cancer cells were
exposed to the proteasomal inhibitor PS-341. Increased
binding between USP9X and Mcl-1 (Figure 4d) was
detected by IP western blot, whilst Mcl-1 expression was
found to be elevated by PS341. PS-341 induced Mcl-1
ubiquitylations were demonstrated in Additional file 1:
Figure S1. These findings confirmed that USP9X is an
Mcl-1 deubiquitinase and thereby regulates Mcl-1
degradation.
Figure 3 Mcl-1 and USP9X are co-overexpressed in colon and lung cancers. (a) Lung adenocarcinoma tissue slides were stained for USP9X
and Mcl-1 proteins. (b) On slides containing colon adenocarcinoma tissue samples, USP9X and Mcl-1 staining was performed. (c) Pearson
correlation between the USP9X and Mcl-1 expression data for 94 lung adenocarcinoma samples was calculated using R statistical software. (d)
Pearson correlation between USP9X and Mcl-1 expression in 79 colon adenocarcinoma samples was determined using R statistical software. (e)
The correlation between USP9X expressions and the clinical staging of different colon cancer samples was determined using linear regression.
The mean levels within each stage, plus or minus one standard error, were plotted.
Peddaboina et al. BMC Cancer 2012, 12:541 Page 7 of 12
http://www.biomedcentral.com/1471-2407/12/541
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Figure 4 USP9X activity regulates Mcl-1 expression. (a) H1299 cells were treated with 10 μM WP1130 for 6 h and the subsequent
downregulation of Mcl-1 was confirmed by western blotting. No change was observed in the Bcl-xL protein levels. The β-Actin expression levels
were detected to normalize for protein loading. Proteins were quantified using the UN-SCAN-IT automatic digitizing system. Those intensities of
the signals of Bcl-xl and Mcl-1 are relative to Actin. The mean ± SD represented the triplicate of three repeated western blotting. (b) A549 cells
were plated in 10 cm tissue culture dishes and upon reaching 70% confluency were treated with 10 μg/ml CHX for 6 h or exposed to a
combination of 7.5 μM WP1130 for 2, 4 and 6 h and 10 μg/ml CHX for 6 h. Mcl-1 and USP9X signals were then determined by western blotting.
Proteins were quantified using UN-SCAN-IT. Those intensities of the signals of USP-9X and Mcl-1 are relative to Actin. (c) Mcl-1 proteins were
immunoprecipitated from A549 cell lysates using anti-Mcl-1 antibody or control IgG. USP9X signals were then detected by western blotting. (d)
A549 cells were exposed to a proteasomal inhibitor PS341 for 2, 4 and 6 h and the cells were then harvested and lysed. Mcl-1 was
immunoprecipitated from these lysates with an anti-Mcl-1 antibody. USP9X signals and Mcl-1 signals were then detected by western blotting.
Ub1 represents mono-ubiquitylated Mcl-1. Ub2 represents ubiquitylated Mcl-1 conjugated with two ubiquitins. Ub3 represents ubiquitylated Mcl-
1 conjugated with three ubiquitins.
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chemotherapies
To explore the therapeutic potential of USP9X inhibition
in conjunction with various chemotherapeutics, we eval-
uated the capacity of WP1130 in combination with
ABT-737 to increase the chemosensitivity of H1299 and
A549 cell lines. With concurrent WP1130 treatment in
A549 and H1299 cells, the cytotoxic response to ABT-
737 increased drastically (Figure 5a). Furthermore,
WP1130 was found to sensitize the H1299 cell line
(High Mcl-1 expression), but not the HCT116 cell line
(low Mcl-1 expression), to SAHA and 5-FU treatments
(Figure 5b). Similar sensitization outcomes were
observed in multiple cancer cell lines such as REN,
DLD-1 and LOVO. Western blot analysis of H1299 fur-
ther revealed that a concurrent overnight exposure to
ABT-737 (20 μM) and WP1130 resulted in PARP cleav-
age and cell death, indicating apoptosis induction.
In these treated cells, PARP cleavage increased in a
dose-dependent fashion under exposure to 3 μM, 4 μM,
and 5 μM WP1130 when co-treated with ABT-737
(Figure 5c). Flow cytometric analysis of H1299 cells con-
firmed an increased sensitization to ABT-737 under
WP1130 exposure by revealing that the percentage of
apoptotic cells was significantly higher when cells were
treated with both agents compared with individual treat-
ments (Figure 5d).Discussion
Our present data clearly demonstrate that the overex-
pression of Mcl-1 in coordination with Bcl-2/Bcl-xL
expression protects cancer cells from apoptosis. Mito-
chondria are the main ATP producers in cells and are
therefore essential for all cellular processes. Further-
more, mitochondria play a pivotal role in life or death
decisions in the cell by regulating the apoptosis pathway.
The release of cytochrome C from mitochondria leading
to the activation of caspases is a hallmark of the apop-
totic response. Concomitantly, resistance to apoptosis
can arise from a reduction in mitochondrial outermembrane permeabilization. Akt kinase, autophagy, and
elevated Bcl-xL and Mcl-1 can cooperate to protect
tumor cells against chemotherapy-induced apoptosis by
maintaining mitochondrial stability [24,25]. The NIH
Developmental Therapeutics Program has determined
that Bcl-xL may play a unique role in the general resist-
ance of cancer cells to cytotoxic agents by showing that
a variety of cancer cell lines that demonstrate resistance
to 70,000 cytotoxic agents are characterized by high Bcl-
xL expression [26]. Mcl-1 overexpression has also been
reported to contribute to chemoresistance in multiple
tumors [15,27] and, notably, has been implicated in the
chemoresistance of certain types of malignancies to the
first of a new class of Bcl-2-family targeting compounds,
ABT-737 [28].
Because of the overexpression and overlapping func-
tions of the Bcl-2 family proteins, it will be important to
develop an inhibitor of both Bcl-2/xL and Mcl-1. It has
been shown previously that either Mcl-1 downregulation
or NOXA overexpression, an Mcl-1 specific BH3-only
protein, strongly sensitizes melanoma cells to ABT-737
in vitro [7]. Hence, developing BH3 mimetics could be a
feasible approach to inhibit Mcl-1 function. Unfortu-
nately, none of the BH3 mimetics under current devel-
opment are potent and specific Mcl-1 antagonists [29].
Indeed, many “pan- Bcl2 inhibitors” suffer from a lack of
specificity or are simply too weak to compete with native
high-affinity BH3-only proteins for pro-survival BH3
binding pockets. Further, such pan-Bcl2 family protein
inhibitors might well damage normal tissues. Hence,
BH3 mimetics specific for single pro-survival targets
could have greater clinical utility [30]. Pertinently, GDC-
0199, a novel BH3 mimetic developed by Abbott and
Genentech that is specific for Bcl-2, and which is now
entering clinical trials for lymphoid malignancies, should
avoid the dose-limiting thrombocytopenia associated
with the navitoclax [31]. For these reasons, designing an
Mcl-1 specific inhibitor or searching for alternative tar-
gets for Mcl-1 antagonism has become “popular”.
Our current research suggests that USP9X regulates
Mcl-1 expression in cancer cells. Deubiquitinases have
Figure 5 (See legend on next page.)
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Figure 5 USP9X inhibition sensitizes tumor cells to various chemotherapies. (a) A549 and H1299 cells were seeded into 96 well plates
(5000 cells per well) and then exposed to various combinations of inhibitors including 1 μM WP1130 and different doses of ABT-737. An XTT
assay was performed 72 h after treatment. The data shown are the average of triplicate measurements for each treatment condition. Experiments
were repeated three times. (b) H1299 and HCT-116 cells were seeded into 96 well plates and then exposed to various combinations of WP1130
and either SAHA or 5-FU. An XTT assay was performed 72 h after treatment. The data shown are the average of triplicate measurements for each
treatment condition. Experiments were also repeated three times. (c) WP1130 enhances ABT-737 induced apoptosis. H1299 cells were treated
with different concentrations of WP1130 (0, 3, 4 or 5 μM) in combination with ABT-737 (20 μM) over a 24 h period. The PARP cleavage profile in
these samples was then documented via western blotting using an anti-PARP antibody. β-actin was detected as a loading control. (d) The
apoptotic cell population following various WP1130 and ABT-737 treatments was stained with Annexin-V and quantified using flow cytometry.
The data shown are the average of quadruplicate assessments for each condition. Experiments were repeated twice.
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oncogenic and tumor suppressive E3-ligases and are
viewed as emerging targets for cancer therapeutics [32].
USP9X can now be added to this list due to its role in
deubiquitination and in stabilizing Mcl-1, a bona fide
oncogene. In our current analyses, USP9X expression
was found to be strongly associated with Mcl-1 expres-
sion in the human cancer tissue samples we tested.
Recent reports have suggested also that USP9X enhances
Mcl-1 stability by preventing its proteasomal destruction
through de-ubiquitination [33]. The balance between
ubiquitination and deubiquitination determines Mcl-1
stability and expression. Ubiquitination of Mcl-1 pro-
motes USP9X-Mcl-1 binding leading to Mcl-1 deubiqui-
tination and disassociation of these two proteins. Hence,
and as shown from our current data, increasing Mcl-1
ubiquitination via PS341 promotes the association of
USP9X with Mcl-1. Since Mcl-1 proteins are constantly
ubiquitinated, their association with USP9X appears to
be a “steady-state” condition. This activity and upregula-
tion of USP9X as well as Mcl-1 have been associated
with a poor prognosis and with chemoresistance in a
number of cancers. To determine the impact of USP9X
inhibition on cancer cell survival in our present experi-
ments, we used its inhibitor WP1130 and found that the
treated cells showed Mcl-1 downregulation which
increased their sensitivity to ABT-737 as well as to other
chemotherapeutic agents. In light of the importance of
USP9X in the control of Mcl-1 levels, compounds such
as WP1130 or other more specific inhibitors may be
useful in overcoming the apoptotic resistance associated
with USP9X activity and Mcl-1 protection. WP1130 may
therefore have utility as a chemosensitizer in a combin-
ational chemotherapy regimen as it can inhibit several
USPs including USP9X, USP5, USP14, and UCH37,
which are known to regulate cell survival, protein
stability, and 26S proteasomal function [34]. Further-
more, USP9X is a deubiquitinase that targets multiple
proteins involved in cell growth and survival [35,36].
Hence, the design of a specific inhibitor that targets the
USP9X and Mcl-1 interaction could also be a viable and
possibly even a better approach to reducing the impact
of chemoresistance in different tumors.Conclusions
Our current analyses demonstrate in principle that the
expression of USP9X, Mcl-1 and Bcl-xL contributes to
chemoresistance in cancer cells. Promoting Mcl-1 ubi-
quitination and degradation using USP9X inhibitor sen-
sitizes tumor cells to various chemotherapies including
Bcl-2/Bcl-xL inhibitors.
Additional file
Additional file 1: Figure S1. A549 cells were exposed to a proteasomal
inhibitor PS341 for 2, 4 and 6 h and the cells were then harvested and
lysed. Ubiquitylated proteins were immunoprecipitated from these lysates
using ubiquitin protein enrichment kit from Pierce. Ubiquitylated Mcl-1
signals were then detected by western blotting. Experiments were
repeated twice.
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